Leukemia, other, Phase II

A Phase 2 Study of Donor-Derived Multi-Tumor-Associated Antigen Specific T Cells (MT-401) Administered to Patients With Acute Myeloid Leukemia (AML) Following Hematopoietic Stem Cell Transplantation

Volunteers
Health Professionals

What is the purpose of this trial?

This study is a Phase 2 multicenter study with a Safety Lead-in evaluating safety and efficacy of MT-401 administration to patients with AML, who have received their first allogeneic HSCT. The dose administered is 50 x 10^6 cells (flat dosing).

Find out more about who can participate in this trial

Contact Information

For more information about this study, including how to volunteer, contact Ria Syam

Help Us Discover!

You can help our team find trials you might be eligible for by creating a volunteer profile in MyChart. To get started, create a volunteer profile, or contact helpusdiscover@yale.edu, or call 877.978.8343 for more information.

Create a volunteer profile

Principal Investigator

Lohith Gowda, MD, MRCP
Assistant Professor of Medicine (Hematology); Assistant Professor of Medicine (Hematology), Internal Medicine

Sub-Investigators

Last Updated
04/30/2023
Study HIC
#2000029668